To a question about the cost of biologics from the audience after her talk, Dr. Hahn said that clinicians must look beyond the bottom line: “If in fact your intervention costs $30,000 a year, but people have a better quality of life for 20 or 30 years, that intervention might be cost effective.”
You Might Also Like
Explore This IssueJuly 2014
Also By This Author
At the end of her talk, which preceded a luncheon held in her honor, session moderator Gary R. Feldman, MD, FACR, announced that the CRA would be funding a rheumatology fellowship in Dr. Hahn’s name.
Gretchen Henkel is a medical journalist based in California.
- Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2014 May 16. pii: annrheumdis-2013-205171.
- Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. Nov 2012;71(11):1771–1782.
- Condon MB, Ashby D, Pepper RJ. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280–1286.